U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. High Spot Health Technology Co. Ltd. - 471170 - 12/07/2017
  1. Warning Letters

CLOSEOUT LETTER

High Spot Health Technology Co. Ltd. MARCS-CMS 471170 —

Recipient:
High Spot Health Technology Co. Ltd.

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

 
 
10903 New Hampshire Avenue
Silver Spring, MD 20993 

December 7, 2017

Hsin Yuan Chen
Chief Executive Officer
High Spot Health Technology Co. Ltd.
102 Dung Sei 7th Road, Da-An District
Taichung City, Taiwan 43954

Dear Mr. Chen:

The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter [CMS Case #471170] dated August 25, 2015. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Valerie A. Flournoy
Acting Director
Division of Manufacturing and Quality
Office of Compliance
Center for Devices and Radiological Health

Back to Top